Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex (Nasdaq: VRTX) announced FDA acceptance of its Biologics License Application for povetacicept in adults with IgA nephropathy, with a PDUFA target action date of November 30, 2026.
The Phase 3 RAINIER trial met primary and secondary endpoints, showing large reductions in proteinuria, Gd-IgA1 and hematuria, with a generally favorable safety profile.
Vertex (Nasdaq: VRTX) announced executive participation in two May 2026 investor conferences. Chief Operating and Financial Officer Charlie Wagner will join a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026, at 2:35 p.m. ET.
Chief Executive Officer and President Dr. Reshma Kewalramani will participate in a fireside chat at Bernstein’s 42nd Annual Strategic Decisions Conference on May 29, 2026, at 9:00 a.m. ET.
Vertex (NASDAQ: VRTX) signed a reimbursement agreement with the GKV-Spitzenverband to secure sustainable access in Germany for CASGEVY (exagamglogene autotemcel), a one-time CRISPR/Cas9 gene-edited therapy for eligible patients aged 12 and older with severe sickle cell disease or transfusion-dependent beta thalassemia.
Germany joins multiple countries with reimbursement coverage for CASGEVY as Vertex continues working with payers to expand sustainable patient access.
Vertex (Nasdaq: VRTX) reported Q1 2026 revenue of $2.99 billion, an 8% increase versus Q1 2025, with GAAP net income of $1.0 billion and non-GAAP net income of $1.1 billion. Cash, cash equivalents, and marketable securities were $13.0 billion at March 31, 2026.
Vertex reiterated full-year 2026 revenue guidance of $12.95–$13.1 billion and non-CF revenue of $0.5 billion or greater. Pipeline highlights include a completed rolling BLA submission for povetacicept in IgA nephropathy, U.S. pediatric submission for CASGEVY, and continued commercial traction for JOURNAVX and CF therapies.
Vertex (Nasdaq: VRTX) will report first quarter 2026 financial results on Monday, May 4, 2026 after market close, followed by a conference call and webcast at 4:30 p.m. ET.
Participants may join by phone or via the live webcast on the company website in the Investors section; an archived webcast will be available afterward.
Vertex (NASDAQ: VRTX) announced U.S. FDA label expansions for ALYFTREK and TRIKAFTA, extending ALYFTREK to people with CF ages 6+ and TRIKAFTA to ages 2+ when variants are responsive or produce CFTR protein. The expansions cite responses for 564 variants (ALYFTREK) and 521 variants (TRIKAFTA), adding ~800 eligible U.S. patients and bringing coverage to ~95% of people with CF in the U.S.
The labels include prominent safety guidance on drug-induced liver injury, hypersensitivity, intracranial hypertension, neuropsychiatric events, and recommended monitoring schedules.
Vertex (Nasdaq: VRTX) reported positive Week 36 interim Phase 3 RAINIER results for povetacicept in adults with IgA nephropathy (IgAN). The trial met its primary and two alpha-controlled secondary endpoints with statistically significant reductions: UPCR -49.8% vs placebo (P<0.0001), Gd-IgA1 -79.3% vs placebo (P<0.0001), and hematuria resolution +61.7% vs placebo (P<0.0001).
Povetacicept was generally safe and well tolerated, with no deaths or opportunistic infections reported. Vertex will complete its BLA submission by end of March and is pursuing potential FDA accelerated approval with a priority review voucher.
Vertex (Nasdaq: VRTX) will participate in two investor conferences in March 2026. Management will join fireside chats at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 11:30 a.m. ET.
Speakers include Charlie Wagner and Duncan McKechnie at Leerink, and Susie Lisa and Miroslava Minkova at Barclays.
Vertex (Nasdaq: VRTX) announced Phase 4 data showing JOURNAVX (suzetrigine) enabled opioid-free recovery in plastic surgical patients. In a 99-patient, open-label study, 90.9% were opioid free through treatment (up to 14 days) and 90.7% rated effectiveness as excellent, very good, or good (95% CI: 83.1%, 95.7%). No serious adverse events related to JOURNAVX were reported. Data accepted for oral presentation at AAPM PainConnect 2026 on March 6, 2026.
Vertex (NASDAQ: VRTX) management will participate in TD Cowen’s 46th Annual Health Care Conference on March 3, 2026. CEO Reshma Kewalramani will appear in a fireside chat at 9:10 a.m. ET. A live webcast and archived replay will be available in the Investors > News and Events section.